Immunosuppressants - Israel

Israel

In Israel, the Immunosuppressants market is expected to witness significant growth in the coming years.
By 2024, the projected revenue for this market is estimated to reach US$106.20m.
This forecast indicates a positive trend, with an anticipated annual growth rate (CAGR 2024-2029) of 15.25%.
Looking ahead, the Immunosuppressants market is predicted to expand further, with a market volume of US$215.90m by 2029.
This growth can be attributed to various factors, including advancements in medical research and an increasing demand for immunosuppressant medications.
When comparing the Immunosuppressants market globally, it is noteworthy that United States is expected to generate the highest revenue.
In 2024 alone, the revenue United States is projected to reach a substantial amount of US$35,470.00m.
These figures underscore the significance of the Immunosuppressants market, both in Israel and on a global scale.
With continuous advancements and increasing demand, this market is poised for further growth in the coming years.
Israel is experiencing a growing demand for immunosuppressants due to its high prevalence of autoimmune diseases.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The market for Immunosuppressants in Israel has been witnessing some interesting trends and developments in recent times.

Customer preferences: Patients in Israel who require immunosuppressants have been increasingly opting for branded drugs over generic ones. This is due to the perception that branded drugs are of better quality and are more effective in treating their conditions. Additionally, patients in Israel are known to be more inclined towards natural and alternative medicines, which has led to a rise in demand for herbal immunosuppressants.

Trends in the market: One of the major trends in the immunosuppressants market in Israel is the increasing use of biologics. Biologics are drugs that are made from living organisms and are used to treat a variety of autoimmune diseases. The demand for biologics in Israel has been growing steadily due to their high efficacy and the fact that they have fewer side effects compared to traditional immunosuppressants.Another trend that has been observed in the market is the increasing use of combination therapies. Combination therapies involve the use of two or more drugs to treat a particular condition. This approach has been gaining popularity in Israel as it has been found to be more effective in controlling autoimmune diseases.

Local special circumstances: Israel has a highly advanced healthcare system, which has been a major factor in the growth of the immunosuppressants market. The country has a large number of hospitals and clinics that specialize in treating autoimmune diseases, which has led to a high demand for immunosuppressants.Additionally, Israel has a large population of immigrants who come from countries where autoimmune diseases are more prevalent. This has led to a higher incidence of autoimmune diseases in Israel, which in turn has driven the demand for immunosuppressants.

Underlying macroeconomic factors: The Israeli government has been investing heavily in the healthcare sector, which has led to the development of advanced medical infrastructure in the country. This has created a favorable environment for pharmaceutical companies to develop and market immunosuppressants.Furthermore, Israel has a strong research and development ecosystem, which has led to the development of innovative immunosuppressants. This has helped the country to become a hub for biotech startups and has led to the growth of the immunosuppressants market.In conclusion, the immunosuppressants market in Israel has been witnessing some interesting trends and developments. The increasing use of biologics and combination therapies, as well as the preference for branded drugs and natural medicines, are some of the factors that are shaping the market. The country’s advanced healthcare system, high incidence of autoimmune diseases, and favorable macroeconomic factors are also contributing to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.